Cargando…
What is new in the treatment of advanced melanoma? State of the art
The incidence of melanoma is increasing steadily both in Poland and worldwide. Until 2010 three drugs were approved for the treatment of metastatic melanoma – dacarbazine (DTIC) in Europe and USA, fotemustine in Europe and interleukin-2 (IL-2) in USA. Approval of ipilimumab and vemurafenib in Europe...
Autor principal: | Mackiewicz, Jacek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687450/ https://www.ncbi.nlm.nih.gov/pubmed/23788912 http://dx.doi.org/10.5114/wo.2012.31763 |
Ejemplares similares
-
Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017) -
Recent advances in melanoma treatment – American Society of Clinical Oncology (ASCO) 2012 perspective
por: Mackiewicz, Jacek, et al.
Publicado: (2012) -
BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018) -
Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma
por: Jacek, Mackiewicz, et al.
Publicado: (2015) -
Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)